Abstract：Objective: To observe the clinical curative effect of sulperazone combined with ambroxol hydrochloride on neonatal infectious pneumonia, and to explore their influences on respiratory flora and immune status. Methods: The clinical case data of 98 neonates with infectious pneumonia who were admitted to the hospital from October 2017 to October 2019 were retrospectively analyzed. According to different medication methods, they were divided into control group (n=46) and combination group (n=52). The control group was given sulperazone for anti-infective treatment on basis of routine oxygen inhalation and nutritional support, while combination group was given ambroxol hydrochloride for aerosol inhalation on basis of control group. The clinical curative effect, changes in arterial oxygen partial pressure (PaO2) and arterial partial pressure of carbon dioxide (PaCO2), disappearance time of clinical symptoms, length of hospital stay, immunoglobulin (IG) level and adverse reactions were compared between the two groups. Results: The total response rate in combination group was higher than that in control group (P<0.05). After treatment, level of PaO2 was increased in both groups, and the combination group had larger rangeability than control group (P<0.05). After treatment, level of PaCO2 was decreased in both groups, and the combination group had larger rangeability than control group (P<0.05). The disappearance time of asthma and lung signs in combination group were earlier than that in control group, and hospital stay was significantly shorter than that in control group (P<0.05). After treatment, levels of IgM, IgA, and IgG in combination group were higher than those in control group (P<0.05). There was no significant difference in total incidence of adverse reactions between the two groups (P>0.05). Conclusion: The curative effect of sulperazone combined with ambroxol hydrochloride for aerosol inhalation neonatal is significant on neonatal pneumonia. It can effectively improve arterial blood gas, promote disappearance of clinical symptoms, and shorten the course of disease.
苏丽娜, 李文琳, 陈彩华, 庄太平, 杜积昌, 唐闻琼. 舒普深联合氨溴索治疗新生儿感染性肺炎疗效及对免疫状况的影响[J]. 河北医学, 2020, 26(10): 1754-1758.
SU Lina, LI Wenlin, CHEN Caihua, et al. Curative Effect of Sulperazone Combined with Ambroxol on Neonatal Infectious Pneumonia and Their Influences on Immunity. HeBei Med, 2020, 26(10): 1754-1758.
[1] 梁景忠,何晓娜,贾圆圆.头孢哌酮舒巴坦钠联合盐酸氨溴索治疗新生儿感染性肺炎疗效观察[J].北方药学,2018,15(5):136~137. [2] 黄建军,江文辉,童志杰,等.头孢哌酮/舒巴坦与哌拉西林/他唑巴坦治疗儿童肺炎克雷伯菌肺炎的效果比较[J].广东医学,2016,37(2):187~188. [3] Plomer M , De Z J . More than expectorant: new scientific data on ambroxol in the context of the treatment of bronchopulmonary diseases.[J]. MMW Fortschr Med, 2017, 159(5):22~33. [4] 胡亚美,江载芳.诸福棠实用儿科学[M].第7版.北京:人民卫生出版社,2002.1175. [5] 李婕.沐舒坦不同用药途径对新生儿肺炎的白细胞、降钙素原及超敏C反应蛋白的影响分析[J].基因组学与应用生物学,2016,35(5):1081~1087. [6] 郑春晨,佘晖,董芳.不同剂量替加环素联合头孢哌酮舒巴坦钠对肺部多重耐药菌感染患者凝血功能的影响[J].中国现代医生,2019,57(36):11~14. [7] 许姜姜,高洁,郭骏华,等.2012至2017年某儿童专科医院住院患儿医院感染的部位及病原体分布[J].中国循证儿科杂志,2018,13(4):264~268. [8] 王侃,赵白云,缪晓青,等.盐酸氨溴索辅助治疗新生儿感染性肺炎的疗效与相关药理机制研究[J].中华医院感染学杂志,2019,29(11):1713~1716. [9] 芦红茹,成大欣,马小宁,等.氨溴索对新生儿肺炎TB淋巴细胞亚群及免疫球蛋白的影响观察[J].河北医学,2016,22(11):1771~1774.
2020, Vol. 26 
冀公网安备13080202000677号